Attention Deficit Hyperactivity Disorder
Also known as: ADHD, Atten deficit hyperactivity disorder, Disorder, Syndrome, Diseases
Methodology & AI Transparency ⓘ
Attention Deficit Hyperactivity Disorder Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: What is attention deficit hyperactivity disorder (ADHD)? ADHD is a neurodevelopmental disorder.
- 2 Real-world patient consensus: Synonyms for Attention Deficit Hyperactivity Disorder (F90.9): ADHD, Atten deficit hyperactivity disorder, Disorder (ADHD & Focus).
- 3 Typical cash cost range: Differential triage of Attention Deficit Hyperactivity Disorder (F90.9) utilizes structured behavioral + in Attention Deficit Hyperactivity Disorder (F90.9: pharmacologic titration monitoring).
- 4 Top reported side effects / signs: Objective lab/clinical target for Attention Deficit Hyperactivity Disorder: Resting Blood Pressure in Attention Deficit Hyperactivity Disorder (F90.9: & Pulse (on) (< 125/80 mmHg; HR < 85 bpm (F90.9)) and Serum Ferritin & in Attention Deficit Hyperactivity Disorder (F90.9: Iron Saturation).
Ask our AI Specialists anything about Attention Deficit Hyperactivity Disorder
What Is Attention Deficit Hyperactivity Disorder?
What is attention deficit hyperactivity disorder (ADHD)? ADHD is a neurodevelopmental disorder. It is usually first diagnosed in childhood and often lasts into adulthood. But some people don't get diagnosed with ADHD until they are adults. ADHD involves: Having trouble paying attention (inattention) Having trouble controlling impulsive behaviors (impulsivity) Being overly active (hyperactivity) What are the types of attention deficit hyperactivity disorder (ADHD)? There are three types of ADHD: Mostly Inattentive ADHD. People with this type of ADHD have trouble paying attention and are easily distracted. It's hard for them to organize or finish tasks.
Pathophysiology, Underlying Causes & Clinical Presentation
Pathophysiologically, Attention Deficit Hyperactivity Disorder (ICD-10 F90.9) is driven by prefrontal cortex catecholaminergic in Attention Deficit Hyperactivity Disorder (F90.9: (dopamine D1); Cross-referenced with NIH MeSH (Attention Deficit Disorder with Hyperactivity), specialists in ADHD, Autism & Behavioral Health monitor Serum Ferritin & in Attention Deficit Hyperactivity Disorder (F90.9: Iron Saturation) to gauge tissue recovery.
Common Symptoms & Clinical Signs
- • Having trouble paying attention (inattention)
- • Having trouble controlling impulsive behaviors (impulsivity)
- • Presentation of Attention Deficit Hyperactivity Disorder (F90.9): difficulty sustaining focus in Attention Deficit Hyperactivity Disorder (F90.9: on sequential or)
- • Secondary Attention Deficit Hyperactivity Disorder clinical sign: time blindness, working-memory in Attention Deficit Hyperactivity Disorder (F90.9: slips, and chronic)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Attention Deficit Hyperactivity Disorder Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | F90.9 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | ADHD, Autism & Behavioral Health | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: Resting Blood Pressure in Attention Deficit Hyperactivity Disorder (F90.9: & Pulse (on) | < 125/80 mmHg; HR < 85 bpm (F90.9) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Serum Ferritin & in Attention Deficit Hyperactivity Disorder (F90.9: Iron Saturation) | Ferritin 50 – 120 ng/mL (F90.9) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: ASRS-v1.1 / Vanderbilt in Attention Deficit Hyperactivity Disorder (F90.9: Executive Score) | Functional symptom control (F90.9) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Attention Deficit Hyperactivity Disorder
| Medication | Pharmacologic Class | Patient Worth-It | CMS NADAC / Unit | Typical Lowest Cash |
|---|---|---|---|---|
| Strattera (Atomoxetine Hydrochloride) Strattera • RxCUI 349592 | Norepinephrine Reuptake Inhibitor | 78% | $12.6575 | $ 9.06 /mo |
| Dexmethylphenidate Hydrochloride Focalin • RxCUI 899518 | Central Nervous System Stimulant | 87% | $0.1859 | $ 16.03 /mo |
| Methylphenidate Hydrochloride Metadate Cd, Relexxii • RxCUI 1091133 | Central Nervous System Stimulant | 83% | $14.9660 | $ 185.00 /mo |
| Lisdexamfetamine Dimesylate Vyvanse • RxCUI 854830 | Central Nervous System Stimulant | 74% | $2.5421 | $ 111.46 /mo |
| Atomoxetine Hydrochloride Strattera, Atoncy • RxCUI 349591 | Norepinephrine Reuptake Inhibitor | 90% | $12.6575 | $ 9.06 /mo |
| Colestid (Colestipol Hydrochloride) Colestid • RxCUI 1048447 | Bile Acid Sequestrant | 89% | $0.6743 | $ 16.67 /mo |
| Methamphetamine Hydrochloride Methamphetamine Hydrochloride Generic • RxCUI 977860 | Amphetamine Anorectic | 80% | $5.0978 | $ 185.00 /mo |
| Guanfacine Intuniv, Tenex • RxCUI 862006 | Central alpha-2 Adrenergic Agonist | 75% | $0.1690 | $ 6.71 /mo |
| Methylphenidate Hydrochloride Extended Release Methylphenidate Hydrochloride Extended Release Generic • RxCUI 1091145 | Central Nervous System Stimulant | 83% | $0.4374 | $ 26.22 /mo |
| Atoncy (Atomoxetine Hydrochloride) Atoncy • RxCUI 608139-B30698456 | Norepinephrine Reuptake Inhibitor | 86% | $0.4195 | $ 38.70 /mo |
| Atomoxetine Strattera • RxCUI 349595 | Norepinephrine Reuptake Inhibitor | 88% | $0.4975 | $ 9.06 /mo |
| Methylphenidate Daytrana, Cotempla Xr-Odt • RxCUI 753436 | Central Nervous System Stimulant | 94% | $5.7703 | $ 185.00 /mo |
| Dextroamphetamine Sulfate Zenzedi, Dexedrine Spansule • RxCUI 884385 | Central Nervous System Stimulant | 77% | $0.5765 | $ 31.85 /mo |
| Colestipol Hydrochloride Colestid • RxCUI 1048445 | Bile Acid Sequestrant | 89% | $0.6533 | $ 16.67 /mo |
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Attention Deficit Hyperactivity Disorder)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Centanafadine for Attention-Deficit/Hyperactivity Disorder in Adolescents: A: What a 459-Participant Study Found Centanafadine 328.8 mg was efficacious for ADHD treatment in adolescents. Journal of the American Academy of Child and Adolescent Psychiatry • 2026-06-15 • Phase III Randomized Trial | N = 459 | 93/100 | PMID 40619095 ↗ |
| Can This Approach Help? Inside the Latest Research on Effect of intranasal orexin-A (hypocretin-1) on sleep, wakefulness and attention In the test of divided attention, patients had fewer false reactions after orexin-A administration. Behavioural brain research • 2014-04-01 • Randomized Controlled Trial | Multi-cohort | 88/100 | PMID 24406723 ↗ |
| Can This Approach Help? Inside the Latest Research on Benefits and safety of Trimodal Dexmethylphenidate (CTx-1301) in Children and CTx-1301 demonstrated dose-related improvements in signs and symptoms of ADHD, although statistical significance is not consistent across all dose groups. Journal of child and adolescent psychopharmacology • 2026-12-15 • Phase III Randomized Trial | N = 103 | 88/100 | PMID 42484049 ↗ |
| Can This Approach Help? Inside the Latest Research on Prenatal DHA Dose on Infant Visual However, DHA dose did not affect infant HR, nor did it affect infant performance in the gap-overlap attention task. Developmental psychobiology • 2025-09-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 40791013 ↗ |
| Can This Approach Help? Inside the Latest Research on Efficacy, Safety, and Tolerability of Centanafadine Sustained-Release Tablets in Incidences of serious TEAEs and abuse potential-related AEs were low. Journal of clinical psychopharmacology • 2022-01-15 • Phase III Randomized Trial | N = 149 | 88/100 | PMID 35652746 ↗ |
Attention Deficit Hyperactivity Disorder Patient Community & “People Like Me” Threads
Filter Attention Deficit Hyperactivity Disorder community threads and patient logs by age, biological sex, dosage, and treatment duration.